Pain. Acute Pain
Conditions
Interventions
Intervention 1: Bupivacaine:
Dose: 12.5 mg
Number of using: Once
Factory name: Astra Zeneca
Manufacturing Country's Name: France
Location prescribed: Local injection
Administration time: At the b
Treatment - Drugs
Placebo
Bupivacaine:
Dose: 12.5 mg
Number of using: Once
Factory name: Astra Zeneca
Manufacturing Country's Name: France
Location prescribed: Local injection
Administration time: At the beginning o
Normal Saline:
Dose: 3 ml
Number of using: Once
Factory name: Loghman
Manufacturing Country's Name: Iran
Location prescribed: Local injection
Administration time: At the beginning of the su
Sponsors
Vice chancellor for research, Ahvaz Jundishapur University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to 12 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: The parent's parents consent; Age between 5 and 12 years old; ASA class I Exclusion criteria: History of allergy to Bupivacaine; previous complications with general anesthesia; Heart disease; Difficult Intubation
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: 1,2,4,8,12, 18 and 24 hours after surgery. Method of measurement: Visual Analogue Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Opioid Consumption. Timepoint: 24 hours after surgery. Method of measurement: Milligram. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFahime Atigh
Ahvaz Jundishapur University of Medical Sciences
Outcome results
None listed